TTY Biopharm Co Ltd

The Board of Directors is the highest body to guide and supervise climate change policies and is responsible for decision-making, assessment and monitoring of climate-related issues and matters. The Risk Management Center is the dedicated unit for climate change management. Exercise rights in accordance with the major guidelines of 'climate governance' formulated by the Risk Management Center, and report to the Sustainable Development Committee and the Board of Directors every year on the progress of the Company's goals in response to climate change. In addition, to enhance the awareness of climate change among those in charge of governance, the Company organizes education and training on responding to climate change. [...] The Ethical Corporate Management Promotion Center is divided into an administrative management team and a whistleblowing and investigation team. Under the Finance Department's responsibility, the Administrative Management Division is primarily tasked with formulating and amending 'Integrity Management Procedures and Code of Conduct' and other related regulations and systems for integrity management, conducting integrity management education and training for the Company, planning whistleblower systems, handling operations related to employees receiving improper benefits, and gathering activities related to integrity management operations. They report annually to the Sustainable Development Committee and the Board of Directors on the results of integrity management operations. The supervisor of the Legal Affairs and Compliance Division is responsible for receiving the whistleblowing mailbox, and reporting the e-mail received by the Sustainable Development Committee on a quarterly basis. When a whistleblowing incident occurs, the acceptance and investigation team will be activated immediately. Depending on the status of the reported person, the person in charge of the investigation team will appoint members to form an investigation team to investigate the case. The Audit Office checks the receipt of letters to the whistleblower box on a quarterly basis and the operation of ethical corporate management on an annual basis. The Ethical Corporate Management Promotion Center reports to the Sustainable Development Committee and the Board of Directors on the operation of ethical corporate management every year.

The Sustainable Development Committee is subordinated to the Board of Directors, and has 3 functional centers for the promotion and implementation of sustainable strategic goals of the enterprise, the Sustainable Development Promotion Center, the Ethical Management Promotion Center, and the Risk Management Center. There is an executive secretary position served by the corporate governance officer who takes charge of matters such as meetings of the Committee and matters assigned by the Committee. [...] The Sustainable Development Committee convened 7 meetings in year 2022. The Ethical Management Promotion Center reported the ethical management status and proposed to the Sustainable Development Committee a 2023 work plan; organize 2 corporate ethical management promotions and 2 insider trading prevention programs. [...] Regulations: establish Principles of Procedures for Ethical Management, Procedures for Ethical Management and Guidelines for Conduct, Internal Material Information Management and Procedures for the Prevention of Insider Trading for a holistic anti-corruption system. [...] Training: in year 2022, 1 Insider Trading Prevention training was given to 7 directors and 54 senior management staff members, in-person and online; 2 corporate ethical management and 2 insider trading prevention courses were attended by all employees, with 100% completion of online learning and tests. [...] Reporting mailbox: dedicated personnel report non-advertising or spam mail to the Sustainable Development Committee immediately after receipt, which shall then report a summary of mail received quarterly.

報告書發行前,由永續發展推動中心加強審閱,發行後呈交永續發展委員會確認通過,再呈報至董事會檢視通過。

The Sustainable Development Organization Structure To realize corporate governance, environmental sustainability, social welfare, corporate sustainability, and CSR, on October 7th, 2019, the Sustainable Development Committee was established under the Board of Directors with 5 members nominated from the directors based on the BoD resolution. Under the Sustainable Development Committee, the CEO acts as the convener, while the Financial Department ensures that the associated policies are promoted appropriately, and the team makes regular reports to the BoD after reporting to SDC. With respect to the various sectors of ESG, the Sustainable Development Committee comprises 4 teams of Corporate Governance, Sustainable Environmental, Social Welfare, Sustainable Information Disclosure to enact the responsibility of proposing and executing the relevant policies, systems, relevant management guidelines, and specific action plans. To maintain stakeholders' reasonable requests and expectations, each team proposed the performance results and future advanced goals of the sustainable topics that they in charge of respectively. It aims to promote business management continuously and duty of social responsibility. Sustainable Development Organization established the implementation plans for the following year by the end of every year, and proposed to SDC and BoD. The implementation of year 2023 has been reported to SDC and BoD on March 8, 2024 for review, and the 2024 action plan has been reported and approved on November 3, 2023 before executed.

The Company regularly participates the Chinese Association for Pharmaceutical Agents (CAPA) & Taipei Pharmaceutical Agents and Distribution Association (TPADA) meetings integrating the opinions from Taiwan Pharmaceutical Manufacturer's Association (TPMA) in order to take early action. In addition to establishing a complete sales network across Taiwan for the purpose to provide real time service to hospital and clinic and increase the width of sales, the Company also enhances resource utilization effectiveness and focuses on drugs with a certain market scale and value for strategic cooperation, and strengthens patient nursing through collaboration with medical experts, and continues to enhance hospital, clinic and doctor's confidence on drugs for the purpose of boosting opportunity to utilize prescriptions of drug. Additionally, the Company introduces new drug for post-clinical target treatment field through licensing, and complies with pioneering nation's certification timeline in order to shorten time needed for domestic certification, and works with preeminent marketing team and resources in order to create the best product revenue and avoid circumstances of the Company's lowered profitability from the implementation of adjustment in drug price.

永續發展委員會隸屬於董事會,轄下設立「永續發展推動中心」、「誠信經營推動中心」及「風險管理中心」等三個功能中心,以推動與執行公司永續發展策略目標,並設置執行秘書 1 名,由公司治理主管擔任,負責辦理永續發展委員會議事相關事務與執行委員會交辦事項。